Retrophin Inc (NASDAQ:RTRX) insider Noah L. Rosenberg sold 870 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $20.49, for a total value of $17,826.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

RTRX stock opened at $19.88 on Friday. The stock has a market capitalization of $858.02 million, a PE ratio of -9.42 and a beta of 0.86. Retrophin Inc has a 12-month low of $8.98 and a 12-month high of $21.92. The company has a current ratio of 5.97, a quick ratio of 5.88 and a debt-to-equity ratio of 0.92. The stock’s 50 day simple moving average is $19.03 and its 200 day simple moving average is $16.31.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.58). The business had revenue of $48.43 million for the quarter, compared to analysts’ expectations of $48.50 million. Retrophin had a negative return on equity of 39.84% and a negative net margin of 49.13%. On average, research analysts predict that Retrophin Inc will post -1.56 earnings per share for the current year.

RTRX has been the topic of a number of research analyst reports. ValuEngine downgraded Retrophin from a “strong-buy” rating to a “buy” rating in a report on Friday, April 17th. BTIG Research assumed coverage on Retrophin in a research report on Tuesday, June 16th. They issued a “buy” rating and a $25.00 price target on the stock. BMO Capital Markets dropped their price target on Retrophin from $34.00 to $31.00 in a research report on Monday, July 13th. Canaccord Genuity reissued a “buy” rating and issued a $26.00 price target on shares of Retrophin in a research report on Tuesday, May 19th. Finally, Zacks Investment Research raised Retrophin from a “hold” rating to a “strong-buy” rating and set a $23.00 price target on the stock in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Retrophin has an average rating of “Buy” and an average price target of $27.25.

Institutional investors and hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC raised its stake in Retrophin by 103.1% during the 1st quarter. Nisa Investment Advisors LLC now owns 1,970 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,000 shares during the last quarter. Great West Life Assurance Co. Can purchased a new stake in Retrophin during the 4th quarter valued at $50,000. SG Americas Securities LLC purchased a new stake in Retrophin during the 1st quarter valued at $122,000. Calton & Associates Inc. purchased a new stake in Retrophin during the 1st quarter valued at $158,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Retrophin by 256.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,734 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 5,564 shares in the last quarter.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Article: Convertible Shares

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.